
    
      The study will have 2 phases: the Prerandomization Phase and the Randomization Phase. The
      Prerandomization Phase will comprise 3 periods that will last up to a maximum of 35 days: a
      Screening Period, a Run-in Period, and a Baseline Period. The Randomization Phase will
      comprise a Treatment Period during which participants will be treated for 30 nights (1 month)
      and a minimum 14-day Follow-up Period before an End of Study (EOS) Visit (up to 54 days). The
      total study duration for each participant on this study is 89 days.
    
  